Evidence map›Paper›PMID 38978615›Full record

ArticleFrontiers in endocrinology2024

Group-informed attentive framework for enhanced diabetes mellitus progression prediction.

Changting Sheng, Luyao Wang, Caiyi Long, Rensong Yue

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Changting ShengHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Luyao WangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Caiyi LongHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Rensong YueHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing prevalence of Diabetes Mellitus (DM) as a global health concern highlights the paramount importance of accurately predicting its progression. This necessity has propelled the use of deep learning's advanced analytical and predictive capabilities to the forefront of current research. However, this approach is confronted with significant challenges, notably the prevalence of incomplete data and the need for more robust predictive models. Our research aims to address these critical issues, leveraging deep learning to enhance the precision and reliability of diabetes progression predictions. We address the issue of missing data by first locating individuals with data gaps within specific patient clusters, and then applying targeted imputation strategies for effective data imputation. To enhance the robustness of our model, we implement strategies such as data augmentation and the development of advanced group-level feature analysis. A cornerstone of our approach is the implementation of a deep attentive transformer that is sensitive to group characteristics. This framework excels in processing a wide array of data, including clinical and physical examination information, to accurately predict the progression of DM. Beyond its predictive capabilities, our model is engineered to perform advanced feature selection and reasoning. This is crucial for understanding the impact of both individual and group-level factors on deep models' predictions, providing invaluable insights into the dynamics of DM progression. Our approach not only marks a significant advancement in the prediction of diabetes progression but also contributes to a deeper understanding of the multifaceted factors influencing this chronic disease, thereby aiding in more effective diabetes management and research.

Indexed as

Deep LearningDisease ProgressionDiabetes MellitusDiabetes Mellitus, Type 2HumansPrognosisReproducibility of Resultsclusterdeep attentive transformerdiabetes mellitusgroup-level featuresregression

Identifiers

PMID38978615
PMCPMC11228145

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.